Opendata, web and dolomites

COMBACTE-CDI SIGNED

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 COMBACTE-CDI project word cloud

Explore the words cloud of the COMBACTE-CDI project. It provides you a very rough idea of what is the project "COMBACTE-CDI" about.

limited    proof    ecdis    wp2    patient    imi    examined    imi2    efpia    strategies    notably    simulation    authorization    hospitalized    quantification    playing    impacts    realization    clostridium    patients    practices    market    interventions    wp3    guidelines    merger    time    treatment    wps    clustering    prevention    quantify    evaluation    platform    roles    undertaken    drivers    single    packages    health    prevalent    variations    sensitivity    isolates    food    resource    comprising    identification    provision    bacterial    lack    aid    countries    individuals    excellent    combacte    assay    resistance    options    resilience    animal    data    clin    incidence    parallel    difficile    human    harmonise    wp4    net    provides    interrelated    combating    extensive    morbidity    network    recurrence    diagnosis    optimize    economic    interventional    bacte    trial    effectiveness    prior    collected    contemporaneous    clinical    exposed    diagnostics    community    infection    size    economy    surveillance    first    epidemiological    followed    expertise    transmission    multiple    poses    cdi    experts    input    costeffectively    actively    synergistic    lab    citizens    executing    compare    brings    successfully    link    subjects    partnered    collaborative    frequency    enhanced    antibiotics    epidemiology    infections    feasible    mean    therapeutic    laboratory    underestimated    settings    strain    sensitive    usually    models    burden    true    euclid    definition    wp1    mortality    healthcare    create    scientific    conduct    accurate    questionnaire    reduce    diagnostic   

Project "COMBACTE-CDI" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.combacte.com/about/combacte-cdi-understanding-of-the-epidemiology-and-clinical-impact-of-clostridium-difficile-infection/
 Total cost 4˙179˙307 €
 EC max contribution 2˙312˙305 € (55%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-09-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 350˙255.00
2    UNIVERSITY OF LEEDS UK (LEEDS) participant 1˙330˙476.00
3    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 151˙848.00
4    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 150˙260.00
5    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 137˙676.00
6    NACIONALNI LABORATORIJ ZA ZDRAVJE, OKOLJE IN HRANO SI (MARIBOR) participant 90˙557.00
7    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 58˙556.00
8    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 42˙676.00
9    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
10    BIOMERIEUX SA FR (Marcy l'Etoile) participant 0.00
11    DA VOLTERRA SAS FR (PARIS) participant 0.00
12    GLAXOSMITHKLINE BIOLOGICALS SA BE (RIXENSART) participant 0.00
13    PFIZER LIMITED UK (SANDWICH) participant 0.00
14    SANOFI PASTEUR SA FR (LYON) participant 0.00

Map

 Project objective

Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients and individuals in the community; notably, there is an increasing realization that cases also occur in subjects not recently exposed to healthcare interventions, including antibiotics. CDI poses an extensive burden of morbidity, mortality and healthcare resource utilization, and so requires effective prevention and management strategies. Epidemiological data are, however, limited and studies typically have examined only part of a healthcare economy and usually have been focused on single countries/healthcare systems. Thus, there is a lack of robust, comprehensive data on the impact of CDI across countries in Europe. Furthermore, we know that large variations in the frequency of testing and the sensitivity of CDI diagnostics across European countries mean that the size of the problem is underestimated.

Combating Bacterial Resistance in Europe-CDI (COMBACTE-CDI) therefore aims to develop a detailed understanding of the epidemiology and clinical impact of CDI across multiple European countries. Our project proposal provides a collaborative approach comprising three scientific work packages (WPs). A large epidemiology study will be undertaken across Europe in WP1 to quantify the burden of CDI (incidence, distribution, recurrence, morbidity, mortality, transmission) across the whole healthcare economy. This will be followed by a case/control study in WP2, which along with data collected in a questionnaire will enable the consortium to assess current practices in Europe (guidelines, testing, surveillance, treatment, cost) and their potential impacts. WP3 will create a rich, European, research platform that will provide support for future proof-of-concept and clinical studies of new prevention and treatment strategies for CDI. The three interrelated research WPs will be supported by a management work package (WP4).

COMBACTE-CDI will harmonise with many of the IMI2 objectives; specifically, we aim to improve the health of European citizens by providing evidence of the true epidemiology and transmission of CDI. We will also develop ‘best-practice’ models for diagnosis, treatment and surveillance, which should reduce the incidence and impact of CDI (including mortality) across Europe, and will optimize patient management. Notably, in order to deliver these aims costeffectively and to test the resilience of our data, we will actively link and compare our data with other European projects that include CDI as a target condition. This synergistic approach will be all the more feasible as the participants in COMBACTE-CDI are playing key roles in multiple, relevant, parallel European CDI activities.

Our ambitious proposal aims to go beyond the state of the art in 8 aspects: quantification of CDI in the whole healthcare economy; contemporaneous comparison with animal and food isolates with those within human health; identification of potential drivers of strain clustering, providing enhanced information to aid further trial/study design and conduct; use of a novel highly sensitive diagnostic assay for more accurate CDI case definition; provision of both cost-effectiveness and transmission models to enable further evaluation of interventions; and finally, by comparing overall costs in different European healthcare settings, we will, for the first time, allow simulation of the economic impact of novel CDI treatment options, even prior to market authorization.

COMBACTE-CDI is the merger of excellent European expertise on the clinical, diagnostic, and therapeutic issues related to CDI and the expertise and input of 7 EFPIA partners. It brings together experts that partnered in CDI projects (EUCLID, ECDIS-NET), the largest existing (IMI-funded) clinical and laboratory network in Europe (CLIN-Net and LAB-Net) for successfully executing challenging epidemiological and interventional studies related to bacte

 Deliverables

List of deliverables.
Report on heterogeneity of testing and delivery of dataset Documents, reports 2020-02-13 13:11:22
Report on current treatment pathways Documents, reports 2020-02-13 13:11:11
Report on high risk groups and delivery of dataset Documents, reports 2020-02-13 13:11:32
Report on recurrent CDI, morbidity and mortality and delivery of dataset Documents, reports 2020-02-13 13:09:19
Report on current surveillance practices Documents, reports 2020-02-13 13:08:54
Report on current guidelines for diagnosis, management and control of CDI Documents, reports 2020-02-13 13:09:23
Report on strain distribution and delivery of dataset Documents, reports 2020-02-13 13:09:02
Full ethical approval of final study protocol from all countries Documents, reports 2020-01-28 14:45:03
Adaptation of COMBACTE website to include COMBACTE-CDI Websites, patent fillings, videos etc. 2020-01-28 14:45:03

Take a look to the deliverables list in detail:  detailed list of COMBACTE-CDI deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBACTE-CDI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COMBACTE-CDI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More